Copyright Reports & Markets. All rights reserved.

COVID-19 Impact on Global Targeted Drugs for NSCLC Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Targeted Drugs for NSCLC Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global Targeted Drugs for NSCLC Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Target EGFR
    • 1.4.3 Target ALK
    • 1.4.4 Target HER2
    • 1.4.5 Target ROS1
    • 1.4.6 Target BRAF
    • 1.4.7 Target MEK
    • 1.4.8 Target VEGFR2
    • 1.4.9 Target VEGF
    • 1.4.10 Target MET
  • 1.5 Market by Application
    • 1.5.1 Global Targeted Drugs for NSCLC Market Share by Application: 2020 VS 2026
    • 1.5.2 Squamous Cell Carcinoma of NSCLC
    • 1.5.3 Adenocarcinoma of NSCLC
    • 1.5.4 Large Cell Carcinoma of NSCLC
  • 1.6 Coronavirus Disease 2019 (Covid-19): Targeted Drugs for NSCLC Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the Targeted Drugs for NSCLC Industry
      • 1.6.1.1 Targeted Drugs for NSCLC Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and Targeted Drugs for NSCLC Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for Targeted Drugs for NSCLC Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Global Growth Trends by Regions

  • 2.1 Targeted Drugs for NSCLC Market Perspective (2015-2026)
  • 2.2 Targeted Drugs for NSCLC Growth Trends by Regions
    • 2.2.1 Targeted Drugs for NSCLC Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Targeted Drugs for NSCLC Historic Market Share by Regions (2015-2020)
    • 2.2.3 Targeted Drugs for NSCLC Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Targeted Drugs for NSCLC Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Targeted Drugs for NSCLC Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Targeted Drugs for NSCLC Players by Market Size
    • 3.1.1 Global Top Targeted Drugs for NSCLC Players by Revenue (2015-2020)
    • 3.1.2 Global Targeted Drugs for NSCLC Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Targeted Drugs for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Targeted Drugs for NSCLC Market Concentration Ratio
    • 3.2.1 Global Targeted Drugs for NSCLC Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Targeted Drugs for NSCLC Revenue in 2019
  • 3.3 Targeted Drugs for NSCLC Key Players Head office and Area Served
  • 3.4 Key Players Targeted Drugs for NSCLC Product Solution and Service
  • 3.5 Date of Enter into Targeted Drugs for NSCLC Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Targeted Drugs for NSCLC Historic Market Size by Type (2015-2020)
  • 4.2 Global Targeted Drugs for NSCLC Forecasted Market Size by Type (2021-2026)

5 Targeted Drugs for NSCLC Breakdown Data by Application (2015-2026)

  • 5.1 Global Targeted Drugs for NSCLC Market Size by Application (2015-2020)
  • 5.2 Global Targeted Drugs for NSCLC Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Targeted Drugs for NSCLC Market Size (2015-2020)
  • 6.2 Targeted Drugs for NSCLC Key Players in North America (2019-2020)
  • 6.3 North America Targeted Drugs for NSCLC Market Size by Type (2015-2020)
  • 6.4 North America Targeted Drugs for NSCLC Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Targeted Drugs for NSCLC Market Size (2015-2020)
  • 7.2 Targeted Drugs for NSCLC Key Players in Europe (2019-2020)
  • 7.3 Europe Targeted Drugs for NSCLC Market Size by Type (2015-2020)
  • 7.4 Europe Targeted Drugs for NSCLC Market Size by Application (2015-2020)

8 China

  • 8.1 China Targeted Drugs for NSCLC Market Size (2015-2020)
  • 8.2 Targeted Drugs for NSCLC Key Players in China (2019-2020)
  • 8.3 China Targeted Drugs for NSCLC Market Size by Type (2015-2020)
  • 8.4 China Targeted Drugs for NSCLC Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Targeted Drugs for NSCLC Market Size (2015-2020)
  • 9.2 Targeted Drugs for NSCLC Key Players in Japan (2019-2020)
  • 9.3 Japan Targeted Drugs for NSCLC Market Size by Type (2015-2020)
  • 9.4 Japan Targeted Drugs for NSCLC Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Targeted Drugs for NSCLC Market Size (2015-2020)
  • 10.2 Targeted Drugs for NSCLC Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Targeted Drugs for NSCLC Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Targeted Drugs for NSCLC Market Size by Application (2015-2020)

11 India

  • 11.1 India Targeted Drugs for NSCLC Market Size (2015-2020)
  • 11.2 Targeted Drugs for NSCLC Key Players in India (2019-2020)
  • 11.3 India Targeted Drugs for NSCLC Market Size by Type (2015-2020)
  • 11.4 India Targeted Drugs for NSCLC Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Targeted Drugs for NSCLC Market Size (2015-2020)
  • 12.2 Targeted Drugs for NSCLC Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Targeted Drugs for NSCLC Market Size by Type (2015-2020)
  • 12.4 Central & South America Targeted Drugs for NSCLC Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Allergan
    • 13.1.1 Allergan Company Details
    • 13.1.2 Allergan Business Overview and Its Total Revenue
    • 13.1.3 Allergan Targeted Drugs for NSCLC Introduction
    • 13.1.4 Allergan Revenue in Targeted Drugs for NSCLC Business (2015-2020))
    • 13.1.5 Allergan Recent Development
  • 13.2 Amgen
    • 13.2.1 Amgen Company Details
    • 13.2.2 Amgen Business Overview and Its Total Revenue
    • 13.2.3 Amgen Targeted Drugs for NSCLC Introduction
    • 13.2.4 Amgen Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 13.2.5 Amgen Recent Development
  • 13.3 ARIAD Pharmaceuticals (Takeda)
    • 13.3.1 ARIAD Pharmaceuticals (Takeda) Company Details
    • 13.3.2 ARIAD Pharmaceuticals (Takeda) Business Overview and Its Total Revenue
    • 13.3.3 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Introduction
    • 13.3.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 13.3.5 ARIAD Pharmaceuticals (Takeda) Recent Development
  • 13.4 Beacon Pharma Limited
    • 13.4.1 Beacon Pharma Limited Company Details
    • 13.4.2 Beacon Pharma Limited Business Overview and Its Total Revenue
    • 13.4.3 Beacon Pharma Limited Targeted Drugs for NSCLC Introduction
    • 13.4.4 Beacon Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 13.4.5 Beacon Pharma Limited Recent Development
  • 13.5 BeiGene
    • 13.5.1 BeiGene Company Details
    • 13.5.2 BeiGene Business Overview and Its Total Revenue
    • 13.5.3 BeiGene Targeted Drugs for NSCLC Introduction
    • 13.5.4 BeiGene Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 13.5.5 BeiGene Recent Development
  • 13.6 Biocon
    • 13.6.1 Biocon Company Details
    • 13.6.2 Biocon Business Overview and Its Total Revenue
    • 13.6.3 Biocon Targeted Drugs for NSCLC Introduction
    • 13.6.4 Biocon Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 13.6.5 Biocon Recent Development
  • 13.7 Boehringer-Ingelheim
    • 13.7.1 Boehringer-Ingelheim Company Details
    • 13.7.2 Boehringer-Ingelheim Business Overview and Its Total Revenue
    • 13.7.3 Boehringer-Ingelheim Targeted Drugs for NSCLC Introduction
    • 13.7.4 Boehringer-Ingelheim Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 13.7.5 Boehringer-Ingelheim Recent Development
  • 13.8 Celgene Corporation
    • 13.8.1 Celgene Corporation Company Details
    • 13.8.2 Celgene Corporation Business Overview and Its Total Revenue
    • 13.8.3 Celgene Corporation Targeted Drugs for NSCLC Introduction
    • 13.8.4 Celgene Corporation Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 13.8.5 Celgene Corporation Recent Development
  • 13.9 Drug International Limted
    • 13.9.1 Drug International Limted Company Details
    • 13.9.2 Drug International Limted Business Overview and Its Total Revenue
    • 13.9.3 Drug International Limted Targeted Drugs for NSCLC Introduction
    • 13.9.4 Drug International Limted Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 13.9.5 Drug International Limted Recent Development
  • 13.10 Fujifilm Kyowa Kirin Biologics
    • 13.10.1 Fujifilm Kyowa Kirin Biologics Company Details
    • 13.10.2 Fujifilm Kyowa Kirin Biologics Business Overview and Its Total Revenue
    • 13.10.3 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Introduction
    • 13.10.4 Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 13.10.5 Fujifilm Kyowa Kirin Biologics Recent Development
  • 13.11 Genvio Pharma Limited
    • 10.11.1 Genvio Pharma Limited Company Details
    • 10.11.2 Genvio Pharma Limited Business Overview and Its Total Revenue
    • 10.11.3 Genvio Pharma Limited Targeted Drugs for NSCLC Introduction
    • 10.11.4 Genvio Pharma Limited Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 10.11.5 Genvio Pharma Limited Recent Development
  • 13.12 Hetero Drugs
    • 10.12.1 Hetero Drugs Company Details
    • 10.12.2 Hetero Drugs Business Overview and Its Total Revenue
    • 10.12.3 Hetero Drugs Targeted Drugs for NSCLC Introduction
    • 10.12.4 Hetero Drugs Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 10.12.5 Hetero Drugs Recent Development
  • 13.13 ImClone Systems ‎(Eli Lilly)
    • 10.13.1 ImClone Systems ‎(Eli Lilly) Company Details
    • 10.13.2 ImClone Systems ‎(Eli Lilly) Business Overview and Its Total Revenue
    • 10.13.3 ImClone Systems ‎(Eli Lilly) Targeted Drugs for NSCLC Introduction
    • 10.13.4 ImClone Systems ‎(Eli Lilly) Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 10.13.5 ImClone Systems ‎(Eli Lilly) Recent Development
  • 13.14 Incepta Pharmaceuticals
    • 10.14.1 Incepta Pharmaceuticals Company Details
    • 10.14.2 Incepta Pharmaceuticals Business Overview and Its Total Revenue
    • 10.14.3 Incepta Pharmaceuticals Targeted Drugs for NSCLC Introduction
    • 10.14.4 Incepta Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 10.14.5 Incepta Pharmaceuticals Recent Development
  • 13.15 Mylan
    • 10.15.1 Mylan Company Details
    • 10.15.2 Mylan Business Overview and Its Total Revenue
    • 10.15.3 Mylan Targeted Drugs for NSCLC Introduction
    • 10.15.4 Mylan Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 10.15.5 Mylan Recent Development
  • 13.16 Novartis
    • 10.16.1 Novartis Company Details
    • 10.16.2 Novartis Business Overview and Its Total Revenue
    • 10.16.3 Novartis Targeted Drugs for NSCLC Introduction
    • 10.16.4 Novartis Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 10.16.5 Novartis Recent Development
  • 13.17 Pfizer
    • 10.17.1 Pfizer Company Details
    • 10.17.2 Pfizer Business Overview and Its Total Revenue
    • 10.17.3 Pfizer Targeted Drugs for NSCLC Introduction
    • 10.17.4 Pfizer Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 10.17.5 Pfizer Recent Development
  • 13.18 Reliance Lifesciences
    • 10.18.1 Reliance Lifesciences Company Details
    • 10.18.2 Reliance Lifesciences Business Overview and Its Total Revenue
    • 10.18.3 Reliance Lifesciences Targeted Drugs for NSCLC Introduction
    • 10.18.4 Reliance Lifesciences Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 10.18.5 Reliance Lifesciences Recent Development
  • 13.19 Roche
    • 10.19.1 Roche Company Details
    • 10.19.2 Roche Business Overview and Its Total Revenue
    • 10.19.3 Roche Targeted Drugs for NSCLC Introduction
    • 10.19.4 Roche Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 10.19.5 Roche Recent Development
  • 13.20 AstraZeneca
    • 10.20.1 AstraZeneca Company Details
    • 10.20.2 AstraZeneca Business Overview and Its Total Revenue
    • 10.20.3 AstraZeneca Targeted Drugs for NSCLC Introduction
    • 10.20.4 AstraZeneca Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 10.20.5 AstraZeneca Recent Development
  • 13.21 Cipla
    • 10.21.1 Cipla Company Details
    • 10.21.2 Cipla Business Overview and Its Total Revenue
    • 10.21.3 Cipla Targeted Drugs for NSCLC Introduction
    • 10.21.4 Cipla Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 10.21.5 Cipla Recent Development
  • 13.22 Teva
    • 10.22.1 Teva Company Details
    • 10.22.2 Teva Business Overview and Its Total Revenue
    • 10.22.3 Teva Targeted Drugs for NSCLC Introduction
    • 10.22.4 Teva Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 10.22.5 Teva Recent Development
  • 13.23 OSI Pharmaceuticals
    • 10.23.1 OSI Pharmaceuticals Company Details
    • 10.23.2 OSI Pharmaceuticals Business Overview and Its Total Revenue
    • 10.23.3 OSI Pharmaceuticals Targeted Drugs for NSCLC Introduction
    • 10.23.4 OSI Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 10.23.5 OSI Pharmaceuticals Recent Development
  • 13.24 Glenmark Pharmaceuticals
    • 10.24.1 Glenmark Pharmaceuticals Company Details
    • 10.24.2 Glenmark Pharmaceuticals Business Overview and Its Total Revenue
    • 10.24.3 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Introduction
    • 10.24.4 Glenmark Pharmaceuticals Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 10.24.5 Glenmark Pharmaceuticals Recent Development
  • 13.25 Natco Pharma
    • 10.25.1 Natco Pharma Company Details
    • 10.25.2 Natco Pharma Business Overview and Its Total Revenue
    • 10.25.3 Natco Pharma Targeted Drugs for NSCLC Introduction
    • 10.25.4 Natco Pharma Revenue in Targeted Drugs for NSCLC Business (2015-2020)
    • 10.25.5 Natco Pharma Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    This report focuses on the global Targeted Drugs for NSCLC status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Targeted Drugs for NSCLC development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

    The key players covered in this study
    Allergan
    Amgen
    ARIAD Pharmaceuticals (Takeda)
    Beacon Pharma Limited
    BeiGene
    Biocon
    Boehringer-Ingelheim
    Celgene Corporation
    Drug International Limted
    Fujifilm Kyowa Kirin Biologics
    Genvio Pharma Limited
    Hetero Drugs
    ImClone Systems ‎(Eli Lilly)
    Incepta Pharmaceuticals
    Mylan
    Novartis
    Pfizer
    Reliance Lifesciences
    Roche
    AstraZeneca
    Cipla
    Teva
    OSI Pharmaceuticals
    Glenmark Pharmaceuticals
    Natco Pharma

    Market segment by Type, the product can be split into
    Target EGFR
    Target ALK
    Target HER2
    Target ROS1
    Target BRAF
    Target MEK
    Target VEGFR2
    Target VEGF
    Target MET
    Market segment by Application, split into
    Squamous Cell Carcinoma of NSCLC
    Adenocarcinoma of NSCLC
    Large Cell Carcinoma of NSCLC

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    The study objectives of this report are:
    To analyze global Targeted Drugs for NSCLC status, future forecast, growth opportunity, key market and key players.
    To present the Targeted Drugs for NSCLC development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
    To strategically profile the key players and comprehensively analyze their development plan and strategies.
    To define, describe and forecast the market by type, market and key regions.

    In this study, the years considered to estimate the market size of Targeted Drugs for NSCLC are as follows:
    History Year: 2015-2019
    Base Year: 2019
    Estimated Year: 2020
    Forecast Year 2020 to 2026
    For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

    Buy now